Erik A. Bey
Department of Basic Pharmaceutical Sciences
West Virginia University
P.O. Box 9530
Morgantown, WV 26506-9530
Link to CV
Erik A. Bey Ph.D., is an Assistant Professor in the Department of Basic Pharmaceutical Sciences and the Mary Babb Randolph Cancer Center. Dr. Bey’s graduate work was completed in a joint degree program between the Department of Cell Biology (Cleveland Clinic Foundation) and the Cell Regulatory Biology program at Cleveland State University. Dr. Bey’s post-doctoral training at Case Comprehensive Cancer Center (Cleveland, Ohio) and Simmons Comprehensive Cancer Center (University of Texas South Western Medical Center at Dallas) focused on cell stress and cancer nanomedicine. Dr. Bey’s research interest include oxidative stress pathways in normal cells, (namely the NAD(P)H oxidase of human monocytes that produce free radicals for antibacterial defense), and the anti-cancer effects of oxidative stress induced by chemotherapeutics. Dr. Bey has also worked extensively in the fields of radiation therapy and drug delivery, which adds depth to his expertise in the field of lung cancer therapy. Dr. Bey’s work with in vivo models contributed significantly to patents and clinical trials awarded to his postdoctoral institutions. In addition, Dr. Bey received numerous awards allowing his participation in international scientific forums, such as the 2007 AACR/JCA joint conference on lung cancer in Nagoya, Japan and the 2009 international symposium on PARP in Tucson, Arizona. Dr. Bey is a member of AACR and his laboratory will focus on the role of oxidative stress in invasive tumors specializing in animal models of lung cancer.
Case Comprehensive Cancer Center
(Case Western Reserve University)
Simmons Comprehensive Cancer Center
(The University of Texas South Western Medical Center at Dallas)
Cleveland Clinic Foundation (Department of Cell Biology)
Cleveland State University (Cell Regulatory Biology Program)
Clarion University of Pennsylvania (B.S. Biology)
Oxidative stress and carcinogenesis
EMT and MET
Orthotopic tumor implantation
In-vivo drug delivery
Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, Minna JD, Bornmann WG, Gao J, Boothman DA. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc.Natl.Acad.Sci.U.S.A. 2007;104(28):11832-7. PMCID: PMC1913860.
Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, Gao J. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release. 2007;122(3):365-74. PMCID: PMC2064869.
Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009;69(19):7644-52. PMCID: PMC2760010.
*Blanco E, Bey *EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA, Gao J. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 2010;70(10):3896-904. (*contributed equally) PMCID: PMC2873165.
Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clin Cancer Res. 2011;17(2):275-85.
American Association for Cancer Research